Update on colchicine and its mechanism of action

Molad, Yair

doi:10.1007/s11926-002-0073-2

Cited by 183 publications

(131 citation statements)

References 48 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…It has previously been established that the microtubule-depolymerising agent, colchicine, has a significant anti-inflammatory effect. Its mode of action includes modulation of chemokine and prostanoid production and inhibition of neutrophil and endothelial cell adhesion molecules [31]. The present data indicate, for the first time, that microtubule stabilisation with taxol results in an anti-inflammatory effect, indicating that not only the structural integrity of microtubules but also microtubule dynamics are important in inflammatory signalling.…”

Section: Effect Of Taxol On Lps-induced Peritonitissupporting

confidence: 54%

Suppression of endotoxin-induced inflammation by taxol

Mirzapoiazova¹,

Kolosova²,

Moreno³

et al. 2007

European Respiratory Journal

View full text Add to dashboard Cite

The pathogenesis of acute lung injury includes transendothelial diapedesis of leukocytes into lung tissues and disruption of endothelial/epithelial barriers leading to proteinrich oedema. In vitro studies show that the microtubule network plays a role in the regulation of endothelial permeability as well as in neutrophil locomotion. It was hypothesised that the microtubule-stabilising agent, taxol, might attenuate inflammation and vascular leak associated with acute lung injury in vivo.The effect of intravenously delivered taxol was assessed using a model of murine lung injury induced by intratracheal lipopolysaccharide (LPS) administration. Parameters of lung injury and inflammation were assessed 18 h after treatment.Intravenously delivered taxol significantly reduced inflammatory histological changes in lung parenchyma and parameters of LPS-induced inflammation: infiltration of proteins and inflammatory cells into bronchoalveolar lavage fluid, lung myeloperoxidase activity, and extravasation of Evans blue-labelled albumin into lung tissue. Taxol alone (in the absence of LPS) had no appreciable effect on these parameters. In addition to lung proteins, intravenous taxol reduced accumulation of leukocytes in ascitic fluid in a model of LPS-induced peritonitis.Taken together, the present data demonstrate that microtubule stabilisation with taxol systemically attenuates lipopolysaccharide-induced inflammation and vascular leak.

show abstract

Section: Effect Of Taxol On Lps-induced Peritonitissupporting

confidence: 54%

Suppression of endotoxin-induced inflammation by taxol

Mirzapoiazova¹,

Kolosova²,

Moreno³

et al. 2007

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…63 Its method of action includes modulation of chemokine and prostanoid production and inhibition of neutrophil and endothelial cell adhesion molecules. 64 In a double-blind, placebo-controlled study, patients with paroxysmal AF who received radiofrequency ablation treatment were randomized to a 3-month course of colchicine 0.5 mg twice daily or placebo. 65 After 3 months, recurrence of AF was observed in 27 (33.5%) of 80 patients of the placebo group versus 13 (16%) of 81 patients who received colchicine (odds ratio, 0.38; 95% confidence interval, 0.18-0.80).…”

Section: Maintenance Post Ablation Colchicinementioning

confidence: 99%

Status of Antiarrhythmic Drug Development for Atrial Fibrillation

Hanley

Robinson

Kowey

2016

Circ: Arrhythmia and Electrophysiology

View full text Add to dashboard Cite

“…It also acts in the migration of granulocytes and other cells, reducing the activity of phagocytes. 15,16 Colchicine is rapidly absorbed in the jejunum and ileum and its lipophilic nature allows it to be absorbed by multiple cells, binding itself to its primary target which is tubulin. Colchicine is predominantly eliminated by biliary excretion and to a lesser extent (5 to 20%) by the enteric and hepatic cytochrome P 450 system.…”

Section: 14mentioning

confidence: 99%

“…Renal elimination accounts for 10 to 20%. 16 Colchicine has been used in recurrent pericarditis (CORP). This study evaluated and randomized 120 patients with the first recurrence using colchicine or placebo in addition to aspirin or other NSAIDs.…”

Section: 14mentioning

confidence: 99%

Acute pericarditis

Tonini

Melo²,

Fernandes³

2015

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Conflict of interest: noneAcute pericarditis is a common disease caused by inflammation of the pericardium, usually benign and self-limited and can occur as an isolated or as a manifestation of a systemic disease entity. Represents 5% of all causes of chest pain in the emergency room. The main etiology are viral infections, although it can also be secondary to systemic diseases and infections. The main complication of acute pericarditis is pericardial effusion, triggering a cardiac tamponade. The first line of treatment is the use of anti-inflammatory and or acetylsalicylic acid. Most patients have a good initial response to an NSAID associated to colchicine and became asymptomatic within a few days. This review article seeks to contemplate the main clinical findings and armed investigation to optimize the diagnosis of this important disease, as well as addressing their therapeutic management.Keywords: acute pericarditis, pericardial effusion, chest pain, colchicine. clinical definitionThe pericardium is a fibroelastic sac composed of two layers (visceral and parietal), separated by a virtual space called the pericardial cavity, which is filled with 15 to 50 mL of plasma ultrafiltrate in healthy subjects. Acute pericarditis is a common disease caused by inflammation of the pericardium, usually benign and selflimited, and may occur as an isolated entity or as a manifestation of a systemic disease.The real incidence and prevalence of pericarditis is difficult to quantify. Necropsy studies suggest a prevalence of approximately 1%. It affects mainly young males (aged between twenty and fifty years) without previous pathologies and represents 5% of all causes of chest pain in the emergency room. In developed countries, about 80-90% of cases are idiopathic, assuming that its main etiology is viral infection, although it can also be secondary to systemic diseases and infections.

show abstract

Update on colchicine and its mechanism of action

Cited by 183 publications

References 48 publications

Suppression of endotoxin-induced inflammation by taxol

Suppression of endotoxin-induced inflammation by taxol

Status of Antiarrhythmic Drug Development for Atrial Fibrillation

Acute pericarditis

Contact Info

Product

Resources

About